Showing results (161-170 of 247) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinJhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
BMC Cancer|June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
BMC Cancer|June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Cancer|July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNEEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialFunda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerEva Thomas, Josep Tabernero, Monica Fornier, et al.
Molecular Cancer Therapeutics|June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsHoward A Burris, Afshin Dowlati, Rebecca A Moss, et al.
International Journal of Cancer|January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumorsIgnacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Pageof 25